RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+5.61%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$4.8B
AUM Growth
+$4.8B
(-2%)
Cap. Flow
+$51.2M
Cap. Flow
% of AUM
1.07%
Top 10 Holdings %
Top 10 Hldgs %
55.46%
Holding
84
New
7
Increased
20
Reduced
15
Closed
24
Top Buys
| 1 |
Bruker
BRKR
|
$93.6M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$86M |
| 3 |
Orchestra BioMed
OBIO
|
$80.6M |
| 4 |
PTC Therapeutics
PTCT
|
$71.6M |
| 5 |
Axsome Therapeutics
AXSM
|
$49.4M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
$83.7M |
| 2 |
Globus Medical
GMED
|
$55.5M |
| 3 |
Illumina
ILMN
|
$43.7M |
| 4 |
Regenxbio
RGNX
|
$41.9M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$37.3M |
Sector Composition
| 1 | Healthcare | 99.97% |
| 2 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $351M | 7.31% | 3,272,104 -82,199 | -2% | -$8.82M |
|
|
2
PTC Therapeutics
PTCT
$3.92B
| $344M | 7.16% | 7,093,298 +1,477,911 | +26% | +$71.6M |
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $337M | 7.02% | 1,683,362 | – | – |
|
4
Rocket Pharmaceuticals
RCKT
$354M
| $303M | 6.31% | 17,687,772 | – | – |
|
5
Immunocore
IMCR
$1.62B
| $279M | 5.82% | 5,649,943 +90,621 | +2% | +$4.48M |
|
6
Masimo
MASI
$7.59B
| $277M | 5.77% | 1,501,493 | – | – |
|
|
7
Axsome Therapeutics
AXSM
$6.05B
| $233M | 4.86% | 3,780,855 +800,373 | +27% | +$49.4M |
|
8
Penumbra
PEN
$10.6B
| $188M | 3.91% | 673,371 -25,000 | -4% | -$6.97M |
|
9
argenx
ARGX
$43.6B
| $180M | 3.74% | 482,195 | – | – |
|
10
Ultragenyx Pharmaceutical
RARE
$2.89B
| $171M | 3.57% | 4,270,996 +304,081 | +8% | +$12.2M |
|
|
11
Thermo Fisher Scientific
TMO
$186B
| $167M | 3.48% | 290,334 -145,166 | -33% | -$83.7M |
|
12
Establishment Labs
ESTA
$1.2B
| $162M | 3.37% | 2,389,138 +15,000 | +0.6% | +$1.02M |
|
|
13
Acadia Pharmaceuticals
ACAD
$4.38B
| $155M | 3.23% | 8,242,864 +4,571,926 | +125% | +$86M |
|
14
Natera
NTRA
$23.1B
| $145M | 3.02% | 2,611,783 +2,500 | +0.1% | +$139K |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $135M | 2.82% | 3,643,114 | – | – |
|
16
Celldex Therapeutics
CLDX
$1.47B
| $111M | 2.31% | 3,084,215 | – | – |
|
17
Protagonist Therapeutics
PTGX
$3.67B
| $106M | 2.2% | 4,600,799 +1,008,813 | +28% | +$23.2M |
|
|
18
Orchestra BioMed
OBIO
$147M
| $100M | 2.09% | 5,118,507 +4,118,507 | +412% | +$80.6M |
|
19
Avidity Biosciences
RNA
$5.99B
| $98M | 2.04% | 6,387,178 +781,612 | +14% | +$12M |
|
20
Vericel Corp
VCEL
$1.83B
| $96.5M | 2.01% | 3,291,873 +191,969 | +6% | +$5.63M |
|
|
21
Bruker
BRKR
$5.16B
| $93.6M | 1.95% | +1,187,342 | New | +$93.6M |
|
22
Cytokinetics
CYTK
$4.23B
| $90.6M | 1.89% | 2,574,198 | – | – |
|
|
23
Illumina
ILMN
$15.8B
| $87.5M | 1.82% | 376,250 -188,125 | -33% | -$43.7M |
|
|
AVDL
24
Avadel Pharmaceuticals
AVDL
$1.43B
| $52.6M | 1.1% | 5,741,939 | – | – |
|
25
10x Genomics
TXG
$1.74B
| $51.8M | 1.08% | 929,286 +56,694 | +6% | +$3.16M |
|